Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer

Luigi Tarantini; Giovanni Cioffi; Stefania Gori; Fausto Tuccia; Lidia Boccardi; Daniella Bovelli; Chiara Lestuzzi; Nicola Maurea; Stefano Oliva; Giulia Russo; Pompilio Faggiano

doi:10.1016/j.cardfail.2011.10.015

Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer

Luigi Tarantini, Giovanni Cioffi, Stefania Gori, Fausto Tuccia, Lidia Boccardi, Daniella Bovelli, Chiara Lestuzzi, Nicola Maurea, Stefano Oliva, Giulia Russo, Pompilio Faggiano

Research output: Contribution to journal › Article

Abstract

Background: Adjuvant trastuzumab therapy improves survival of human epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). A careful monitoring of cardiac function is needed due to potential trastuzumab cardiotoxicity (Tcardiotox). To date, the incidence, timing, and phenotype of patients with Tcardiotox in clinical practice are not well known. Methods and Results: A total of 499 consecutive HER2-positive women (mean age 55 ± 11 years) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed for 1 year. We evaluated incidence, time of occurrence, and clinical features associated with Tcardiotox. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and at 3, 6, 9, and 12 months during trastuzumab therapy. Tcardiotox was recognized in 133 patients (27%): 102 (20%) showed asymptomatic reduction in LVEF of >10% but ≤20% (grade 1 Tcardiotox); 15 (3%) had asymptomatic decline of LVEF of >20% or

Original language	English
Pages (from-to)	113-119
Number of pages	7
Journal	Journal of Cardiac Failure
Volume	18
Issue number	2
DOIs	https://doi.org/10.1016/j.cardfail.2011.10.015
Publication status	Published - Feb 2012

Keywords

adjuvant chemotherapy
Breast cancer
cardiotoxicity
heart failure
trastuzumab

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.cardfail.2011.10.015

Fingerprint Dive into the research topics of 'Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer'. Together they form a unique fingerprint.

Cite this

Tarantini, L., Cioffi, G., Gori, S., Tuccia, F., Boccardi, L., Bovelli, D., Lestuzzi, C., Maurea, N., Oliva, S., Russo, G., & Faggiano, P. (2012). Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. Journal of Cardiac Failure, 18(2), 113-119. https://doi.org/10.1016/j.cardfail.2011.10.015

Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. / Tarantini, Luigi; Cioffi, Giovanni; Gori, Stefania; Tuccia, Fausto; Boccardi, Lidia; Bovelli, Daniella; Lestuzzi, Chiara; Maurea, Nicola ; Oliva, Stefano; Russo, Giulia; Faggiano, Pompilio.

In: Journal of Cardiac Failure, Vol. 18, No. 2, 02.2012, p. 113-119.

Research output: Contribution to journal › Article

@article{bdca0abc6a9c46f4a8f9e4163fe37eb1,

title = "Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer",

abstract = "Background: Adjuvant trastuzumab therapy improves survival of human epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). A careful monitoring of cardiac function is needed due to potential trastuzumab cardiotoxicity (Tcardiotox). To date, the incidence, timing, and phenotype of patients with Tcardiotox in clinical practice are not well known. Methods and Results: A total of 499 consecutive HER2-positive women (mean age 55 ± 11 years) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed for 1 year. We evaluated incidence, time of occurrence, and clinical features associated with Tcardiotox. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and at 3, 6, 9, and 12 months during trastuzumab therapy. Tcardiotox was recognized in 133 patients (27%): 102 (20%) showed asymptomatic reduction in LVEF of >10% but ≤20% (grade 1 Tcardiotox); 15 (3%) had asymptomatic decline of LVEF of >20% or ",

keywords = "adjuvant chemotherapy, Breast cancer, cardiotoxicity, heart failure, trastuzumab",

author = "Luigi Tarantini and Giovanni Cioffi and Stefania Gori and Fausto Tuccia and Lidia Boccardi and Daniella Bovelli and Chiara Lestuzzi and Nicola Maurea and Stefano Oliva and Giulia Russo and Pompilio Faggiano",

year = "2012",

month = feb,

doi = "10.1016/j.cardfail.2011.10.015",

language = "English",

volume = "18",

pages = "113--119",

journal = "Journal of Cardiac Failure",

issn = "1071-9164",

publisher = "Churchill Livingstone",

number = "2",

}

TY - JOUR

T1 - Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer

AU - Tarantini, Luigi

AU - Cioffi, Giovanni

AU - Gori, Stefania

AU - Tuccia, Fausto

AU - Boccardi, Lidia

AU - Bovelli, Daniella

AU - Lestuzzi, Chiara

AU - Maurea, Nicola

AU - Oliva, Stefano

AU - Russo, Giulia

AU - Faggiano, Pompilio

PY - 2012/2

Y1 - 2012/2

N2 - Background: Adjuvant trastuzumab therapy improves survival of human epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). A careful monitoring of cardiac function is needed due to potential trastuzumab cardiotoxicity (Tcardiotox). To date, the incidence, timing, and phenotype of patients with Tcardiotox in clinical practice are not well known. Methods and Results: A total of 499 consecutive HER2-positive women (mean age 55 ± 11 years) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed for 1 year. We evaluated incidence, time of occurrence, and clinical features associated with Tcardiotox. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and at 3, 6, 9, and 12 months during trastuzumab therapy. Tcardiotox was recognized in 133 patients (27%): 102 (20%) showed asymptomatic reduction in LVEF of >10% but ≤20% (grade 1 Tcardiotox); 15 (3%) had asymptomatic decline of LVEF of >20% or

AB - Background: Adjuvant trastuzumab therapy improves survival of human epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). A careful monitoring of cardiac function is needed due to potential trastuzumab cardiotoxicity (Tcardiotox). To date, the incidence, timing, and phenotype of patients with Tcardiotox in clinical practice are not well known. Methods and Results: A total of 499 consecutive HER2-positive women (mean age 55 ± 11 years) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed for 1 year. We evaluated incidence, time of occurrence, and clinical features associated with Tcardiotox. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and at 3, 6, 9, and 12 months during trastuzumab therapy. Tcardiotox was recognized in 133 patients (27%): 102 (20%) showed asymptomatic reduction in LVEF of >10% but ≤20% (grade 1 Tcardiotox); 15 (3%) had asymptomatic decline of LVEF of >20% or

KW - adjuvant chemotherapy

KW - Breast cancer

KW - cardiotoxicity

KW - heart failure

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84856439776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856439776&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2011.10.015

DO - 10.1016/j.cardfail.2011.10.015

M3 - Article

C2 - 22300778

AN - SCOPUS:84856439776

VL - 18

SP - 113

EP - 119

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 2

ER -